Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

ALKEM is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 0.000000
forwardPE 28.213232
debtToEquity 17.056000
earningsGrowth 0.016000
revenueGrowth 0.107000
grossMargins 0.629170
operatingMargins 0.196150
trailingEps 198.430000
forwardEps 191.116000

ALKEM's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
Alkem Laboratories Limited's low Debt-to-Equity ratio means the company is not over-leveraged, highlighting its conservative use of debt. This suggests reduced financial risk and a stable balance sheet, making Alkem Laboratories Limited a financially resilient company with lower exposure to debt-related pressures.
Alkem Laboratories Limited's forward EPS being lower than its trailing EPS suggests the company is expected to face declining profits. This points to a less favorable financial outlook for the coming year.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

The stock price of ALKEM has frequently been close to the lower end of analysts' projections. This trend indicates potential struggles for the company in achieving the growth anticipated by the market.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


ALKEM has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see ALKEM as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.